Tirzepatide leads to significantly greater weight loss than semaglutide in overweight or obese adults, with no significant difference in gastrointestinal adverse effects.
Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.
Subscribe To Us
By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy
© 2025 Diabetes Prevention Awareness Center.